Adonias Carvalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adonias Carvalho has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ana Cristina Sousa Gramoza Vilarinho Santana
Laboratory of Technological Innovation, Entrepreneurship, Medicines and Related (LITE), Nucleus of Pharmaceutical Technology, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Ana Victória Alves Peres
Universidade Federal do Piauí
1 shared publication - Dalton Dittz
Federal University of Piaui
1 shared publication - Hercília Maria Lins Rolim
Universidade Federal do Piauí
1 shared publication - Izabela Borges C. Lima
Laboratory of Technological Innovation, Entrepreneurship, Medicines and Related (LITE), Nucleus of Pharmaceutical Technology, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Lina Clara Gayoso e Almendra Ibiapina Moreno
Laboratory of Experimental Neurochemistry Research, Federal University of Piaui, Teresina, PI, Brazil; Immunopathology Keizo-Asami Laboratory, Federal University of Pernambuco, Recife, PE, Brazil
1 shared publication
Latest Publications
- Open Access
- 16 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2830
Nanoparticles Obtained from Zein for Encapsulation of Mesalazine
We encapsulated MSZ in zein nanoparticles (NP-ZN) using a desolvation method followed by drying in a mini spray dryer. These nanoparticles exhibited a size of 266.6 ± 52 nm, IPD of 0.14 ± 1.1 and zeta potential of −36.4 ± 1.5 mV, suggesting colloidal stability. Quantification using HPLC showed a drug-loaded of 43.8 µg/mg. SEM demonstrated a spherical morphology with a size variation from 220 to 400 nm. A FTIR analysis did not show drug spectra in the NPs in relation to the physical mixture, which suggests drug encapsulation without changing its chemical structure. A TGA analysis showed thermal stability up to 300 °C. In vitro release studies demonstrated gastroresistance and a sustained drug release at pH 7.4 (97.67 ± 0.32%) in 120 h. The kinetic model used for the release of MSZ from the NP-ZN in a pH 1.2 medium was the Fickian diffusion, in a pH 6.8 medium it was the Peppas–Sahlin model with the polymeric relaxation mechanism and in a pH 7.4 medium it was the Korsmeyer–Peppas model with the Fickian release mechanism, or “Case I”. An in vitro cytotoxicity study in the CT26.WT cell line showed no basal cytotoxicity up to 500 μg/mL. The NP-ZN showed to be a promising vector for the sustained release of MSZ in the colon by oral route.
- 16 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2830
Open AccessNanoparticles Obtained from Zein for Encapsulation of Mesalazine
We encapsulated MSZ in zein nanoparticles (NP-ZN) using a desolvation method followed by drying in a mini spray dryer. These nanoparticles exhibited a size of 266.6 ± 52 nm, IPD of 0.14 ± 1.1 and zeta potential of −36.4 ± 1.5 mV, suggesting colloidal stability. Quantification using HPLC showed a drug-loaded of 43.8 µg/mg. SEM demonstrated a spherical morphology with a size variation from 220 to 400 nm. A FTIR analysis did not show drug spectra in the NPs in relation to the physical mixture, which suggests drug encapsulation without changing its chemical structure. A TGA analysis showed thermal stability up to 300 °C. In vitro release studies demonstrated gastroresistance and a sustained drug release at pH 7.4 (97.67 ± 0.32%) in 120 h. The kinetic model used for the release of MSZ from the NP-ZN in a pH 1.2 medium was the Fickian diffusion, in a pH 6.8 medium it was the Peppas–Sahlin model with the polymeric relaxation mechanism and in a pH 7.4 medium it was the Korsmeyer–Peppas model with the Fickian release mechanism, or “Case I”. An in vitro cytotoxicity study in the CT26.WT cell line showed no basal cytotoxicity up to 500 μg/mL. The NP-ZN showed to be a promising vector for the sustained release of MSZ in the colon by oral route.